Literature DB >> 6290575

Pathogenicity of acyclovir-resistant herpes simplex virus type 1 from an immunodeficient child.

C D Sibrack, L T Gutman, C M Wilfert, C McLaren, M H St Clair, P M Keller, D W Barry.   

Abstract

Sequential isolates of herpes simplex virus type 1 (HSV-1) from a child with severe combined immunodeficiency were examined for sensitivity to acyclovir. Early intravenous courses of acyclovir resulted in dramatic clinical improvement and were associated with the isolation of sensitive strains of HSV-1 (ID50[dose inhibiting 50% of control plaques], 0.010-0.106 microgram/ml), whereas later recurrences following intravenous, oral, and ophthalmic therapy were characterized by low-grade chronic lesions (ID50, 1.04-9.43 microgram/ml) that were unresponsive to acyclovir despite serum levels of up to 10.45 microgram/ml. Diminished sensitivity was associated with reduced viral thymidine kinase activity, and linked resistance with idoxuridine was detected in the isolates from the patient's eye. Intracerebral and cutaneous snout inoculation of a resistant isolate into BALB/c, hairless, and athymic nude mice revealed a 100- to 1,000-fold decrease in virulence as compared with an early sensitive isolate. Acyclovir-resistant HSV-1 can emerge in certain clinical settings but may be associated with diminished virulence.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6290575     DOI: 10.1093/infdis/146.5.673

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  37 in total

1.  Use of a single monoclonal antibody to determine the susceptibilities of herpes simplex virus type 1 and type 2 clinical isolates to acyclovir.

Authors:  Christine Chutkowski; Betty Olson; Ann McDonough; James Mahoney; James J McSharry
Journal:  Clin Diagn Lab Immunol       Date:  2002-11

Review 2.  Resistance of herpesviruses to antiviral drugs.

Authors:  P A Chatis; C S Crumpacker
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191

3.  Clinical isolate of herpes simplex virus type 2 that induces a thymidine kinase with altered substrate specificity.

Authors:  M N Ellis; P M Keller; J A Fyfe; J L Martin; J F Rooney; S E Straus; S N Lehrman; D W Barry
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

Review 4.  Prophylaxis for genital herpes. Should it be used routinely?

Authors:  A Mindel
Journal:  Drugs       Date:  1991-03       Impact factor: 9.546

Review 5.  Antiviral therapy: current concepts and practices.

Authors:  B Bean
Journal:  Clin Microbiol Rev       Date:  1992-04       Impact factor: 26.132

6.  Improved DNA hybridization method for detection of acyclovir-resistant herpes simplex virus.

Authors:  E M Swierkosz; D R Scholl; J L Brown; J D Jollick; C A Gleaves
Journal:  Antimicrob Agents Chemother       Date:  1987-10       Impact factor: 5.191

7.  Problems associated with the use of (E)-5-(2-bromovinyl)-2'-deoxyuridine for typing herpes simplex virus.

Authors:  E M Swierkosz; M Q Arens; K A Rivetna
Journal:  J Clin Microbiol       Date:  1985-03       Impact factor: 5.948

8.  Thymidine kinase-deficient herpes simplex virus type 2 genital infection in guinea pigs.

Authors:  L R Stanberry; S Kit; M G Myers
Journal:  J Virol       Date:  1985-08       Impact factor: 5.103

Review 9.  Persistent herpes simplex virus infection and mechanisms of virus drug resistance.

Authors:  H J Field
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-08       Impact factor: 3.267

10.  Synergistic therapy by acyclovir and A1110U for mice orofacially infected with herpes simplex viruses.

Authors:  M N Ellis; D C Lobe; T Spector
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.